Fleshner NE - Search Results

1

A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.

Hermanns T, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, Bhindi B, Kuk C, Poyet C, Wild PJ, Noon A, Bashir S, Juvet T, Rendon RA, Waltregny D, van der Kwast T, Finelli A, Kulkarni GS, Fleshner NE, Lo K, Bapat B, Zlotta AR. Hermanns T, et al. Among authors: fleshner ne. Urol Oncol. 2020 Jun;38(6):603.e1-603.e7. doi: 10.1016/j.urolonc.2020.01.007. Epub 2020 Feb 18. Urol Oncol. 2020. PMID: 32081560

2

Differences between urologists in United States and Canada in approach to bladder cancer.

Chung D, Hersey K, Fleshner N. Chung D, et al. Urology. 2005 May;65(5):919-25. doi: 10.1016/j.urology.2004.11.028. Urology. 2005. PMID: 15882724

3

Evidence for a biopsy derived grade artifact among larger prostate glands.

Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: fleshner ne. J Urol. 2006 Feb;175(2):505-9. doi: 10.1016/S0022-5347(05)00236-3. J Urol. 2006. PMID: 16406982

4

Surgical wait times for patients with urological cancers: a survey of Canadian surgeons.

Fleshner N, Dranitsaris G, Finelli A, Tsihlias J, Bell D, Gleave M; Canadian surgical wait times (SWAT) initiative. Fleshner N, et al. Can J Urol. 2006 Jun;13 Suppl 3:3-13. Can J Urol. 2006. PMID: 16818006

5

Does prolonging the time to renal cancer surgery affect long-term cancer control: a systematic review of the literature.

Jewett M, Rendon R, Dranitsaris G, Drachenberg D, Tanguay S, Donnelly B, Fleshner N; Canadian surgical wait times (SWAT) initiative. Jewett M, et al. Can J Urol. 2006 Jun;13 Suppl 3:54-61. Can J Urol. 2006. PMID: 16818013 Review.

6

Should finasteride be used to prevent prostate cancer?

Fleshner N, Kulkarni G. Fleshner N, et al. Curr Treat Options Oncol. 2006 Sep;7(5):346-54. doi: 10.1007/s11864-006-0002-0. Curr Treat Options Oncol. 2006. PMID: 16904051 Review.

7

MYH mutations are rare in prostate cancer.

Shin EJ, Chappell E, Pethe V, Hersey K, van der Kwast T, Fleshner N, Bapat B. Shin EJ, et al. J Cancer Res Clin Oncol. 2007 Jun;133(6):373-8. doi: 10.1007/s00432-006-0181-x. Epub 2007 Jan 12. J Cancer Res Clin Oncol. 2007. PMID: 17219200

8

Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.

Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N. Al-Azab R, et al. Urology. 2007 Jan;69(1):103-7. doi: 10.1016/j.urology.2006.09.041. Urology. 2007. PMID: 17270628

9

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: fleshner ne. Cancer. 2007 Jun 15;109(12):2432-8. doi: 10.1002/cncr.22712. Cancer. 2007. PMID: 17497649 Free article.

10

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R; REDEEM Study Group. Fleshner N, et al. Contemp Clin Trials. 2007 Nov;28(6):763-9. doi: 10.1016/j.cct.2007.05.006. Epub 2007 May 29. Contemp Clin Trials. 2007. PMID: 17573244

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

629 results

Search Page